Inhibition of Orthotopic Genital Cancer Induced by Subcutaneous Administration of Human Papillomavirus Peptide Vaccine with CpG Oligodeoxynucleotides as an Adjuvant in Mice.
human papillomavirus
immunosuppression
orthotopic genital cancer
therapeutic vaccine
tumor microenvironment
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2021
2021
Historique:
received:
05
03
2021
accepted:
07
06
2021
entrez:
21
7
2021
pubmed:
22
7
2021
medline:
22
7
2021
Statut:
epublish
Résumé
Persistent high-risk human papillomavirus (HPV) infection is the most common cause of cervical cancer and its precursor lesions. Although prophylactic HPV vaccines have been applied in the general population for the prevention of HPV infections, no licensed therapeutic HPV vaccine is currently available to treat preexisting HPV infections or HPV-associated diseases, including cervical cancer. The most common murine cervical cancer model used for the evaluation of the efficacy of a therapeutic HPV vaccine in preclinical studies is the ectopic model, which is established by the subcutaneous inoculation of tumor cells, such as TC-1 cells, into the flank of an animal. We have previously demonstrated the efficacy of a therapeutic HPV peptide vaccine adjuvanted with unmethylated cytosine-phosphate-guanosine oligodeoxynucleotide in the clearance of ectopic subcutaneous tumors in C57BL/6 mice after vaccination. In the current study, we established orthotopic genital tumors by injecting TC-1 cells into the vaginal submucosa close to the cervix and assessed whether the subcutaneous administration of the therapeutic vaccine could inhibit the growth of genital tumors. Additionally, we evaluated the effect of the vaccination on the tumor microenvironment. The results showed that the vaccination induced an increase in infiltrating CD4+ and CD8+ T cells, a decrease in myeloid-derived suppressor cells and cancer-associated fibroblasts, as well as the differential expression of a panel of cytokines, chemokines, and matrix metalloproteinases within the tumor microenvironment. The administration of the vaccine resulted in the inhibition of established implanted orthotopic genital tumors by inducing strong antitumor immune responses and reversed tolerogenic local immunosuppression in a mouse model of orthotopic genital cancer.
Identifiants
pubmed: 34285577
doi: 10.2147/CMAR.S309226
pii: 309226
pmc: PMC8285235
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5559-5572Informations de copyright
© 2021 Wang et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Oncoimmunology. 2015 Aug 24;5(2):e1081328
pubmed: 27057462
J Exp Med. 2011 Jul 4;208(7):1485-99
pubmed: 21670203
Adv Healthc Mater. 2014 Jul;3(7):1044-52
pubmed: 24339398
Sci Transl Med. 2013 Feb 13;5(172):172fs4
pubmed: 23408051
Am J Reprod Immunol. 2005 May;53(5):208-14
pubmed: 15833098
Nature. 2011 Jun 08;475(7355):222-5
pubmed: 21654748
J Immunol. 2000 Dec 1;165(11):6047-55
pubmed: 11086036
Nat Rev Immunol. 2017 Sep;17(9):559-572
pubmed: 28555670
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Immunol. 2008 Mar 1;180(5):3122-31
pubmed: 18292535
Adv Exp Med Biol. 2016;941:31-77
pubmed: 27734408
Cancer Res. 2010 Nov 1;70(21):8368-77
pubmed: 20940398
Immunity. 2000 Jun;12(6):677-86
pubmed: 10894167
Sci Rep. 2015 Oct 08;5:14896
pubmed: 26447332
Gynecol Oncol. 1999 Jun;73(3):372-82
pubmed: 10366463
Eur J Pharm Biopharm. 2015 Jun;93:127-35
pubmed: 25843238
Stem Cells. 2017 Dec;35(12):2351-2365
pubmed: 29044882
Cancer Microenviron. 2011 Dec;4(3):361-75
pubmed: 21626415
J Exp Med. 2014 Jul 28;211(8):1503-23
pubmed: 25071162
Int Immunopharmacol. 2019 Apr;69:279-288
pubmed: 30743204
Biomed Res Int. 2015;2015:829513
pubmed: 25874230
J Cell Physiol. 2019 Jun;234(6):7983-7993
pubmed: 30317612
Cancer Lett. 2011 Jun 28;305(2):106-12
pubmed: 21190794
Eur J Cancer. 1997 Oct;33(11):1799-804
pubmed: 9470836
Virus Res. 2019 Feb;261:72-80
pubmed: 30599161
BMC Cancer. 2020 Jul 15;20(1):660
pubmed: 32669083
J Biomed Sci. 2016 Nov 4;23(1):75
pubmed: 27809842
Invasion Metastasis. 1994-1995;14(1-6):234-45
pubmed: 7657516
J Exp Med. 2015 Jun 29;212(7):1043-59
pubmed: 26056232
Int J Cancer. 2011 Aug 1;129(3):762-72
pubmed: 21384340
Gynecol Oncol. 1999 Mar;72(3):380-6
pubmed: 10053110
Nat Rev Immunol. 2009 Mar;9(3):162-74
pubmed: 19197294
Vaccines (Basel). 2020 May 29;8(2):
pubmed: 32485935
Rom J Morphol Embryol. 2018;59(2):455-467
pubmed: 30173249
Nanoscale. 2020 Feb 7;12(5):3076-3089
pubmed: 31965136
Int J Gynecol Cancer. 2004 Mar-Apr;14(2):333-40
pubmed: 15086734
Lancet. 2013 Sep 7;382(9895):889-99
pubmed: 23618600
J Immunol. 2014 Jan 15;192(2):817-23
pubmed: 24337379
Gynecol Oncol. 2001 Nov;83(2):348-54
pubmed: 11606096
Int J Cancer. 2017 Mar 15;140(6):1370-1383
pubmed: 27885671
PLoS One. 2015 Feb 17;10(2):e0117417
pubmed: 25689852
Gynecol Oncol. 2008 Sep;110(3 Suppl 2):S4-7
pubmed: 18760711
J Exp Med. 2010 Mar 15;207(3):637-50
pubmed: 20156971
J Transl Med. 2013 Apr 04;11:88
pubmed: 23557172
Trends Immunol. 2016 Mar;37(3):208-220
pubmed: 26858199
Cancer Immunol Immunother. 2020 Dec;69(12):2651-2664
pubmed: 32607768
Mol Med Rep. 2015 Mar;11(3):1566-72
pubmed: 25384676
Semin Cancer Biol. 2000 Dec;10(6):415-33
pubmed: 11170864
Semin Immunol. 2019 Jun;43:101280
pubmed: 31221552